Features Partner Sites Information LinkXpress
Sign In
Demo Company

3-Photon Microscopy Breaks Depth Limit of Current Biological Tissue Imaging

By BiotechDaily International staff writers
Posted on 07 Feb 2013
Print article
Image:  A horizontal frame from 3D reconstructed 3-photon microscopy images in a mouse brain. Red: neurons, blue: blood vessels, dark holes: nonfluorescent neurons (Photo courtesy of Prof. Xu’s laboratory, Cornell University).
Image: A horizontal frame from 3D reconstructed 3-photon microscopy images in a mouse brain. Red: neurons, blue: blood vessels, dark holes: nonfluorescent neurons (Photo courtesy of Prof. Xu’s laboratory, Cornell University).
In a proof-of-concept study of a live mammalian brain, scientists have now shown that 3-photon microscopy enables high-resolution, noninvasive in vivo imaging at unprecedented depths of complex biological tissue, breaking the fundamental depth limit of standard 2-photon microscopy.

The team of scientists, at Cornell University (Ithaca, NY, USA), have demonstrated a three-fold improvement in the depth limit of fluorescence-based biological tissue imaging over the widely used 2-photon microscopy (2PM) based technology (invented at Cornell in 1990). Tissue scattering limits the maximum imaging depth of 2PM to the cortical layer of the mouse brain, and imaging subcortical structures currently requires the removal of overlying brain tissue or the insertion of optical probes. Senior investigator Chris Xu, associate professor of applied and engineering physics, and colleagues have now demonstrated high-resolution, 3D imaging of the subcortical region of a live, intact mouse brain using 3-photon microscopy (3PM) based imaging technology (invented at Cornell in 1995).

The study, published online January 20, 2013, in the journal Nature Photonics, describes 3-photon fluorescence combined with a longer excitation wavelength of the laser pulse to overcome obstacles such as tissue scattering and absorption, which have prohibited high-resolution imaging deep within biological tissues. Dyes and transgenic mice were used to test the 3PM on different fluorescent signals. Using the live mouse brain model, the researchers have proved the principle of 3PM operating at a wavelength of 1,700 nanometers and this, in combination with the new laser developed specifically for 3-photon excitation, allowed for the high-resolution imaging at unprecedented depths within the brain—vascular structures as well as neurons within the mouse hippocampus were imaged.

"With MRI, we can see the whole brain but not with the resolution we have demonstrated. The optical resolution is about 100 to 1,000 times higher and allows us to clearly visualize individual neurons," said Prof. Xu. Pushing these depth limits is important for basic science and could also prove useful clinically, Prof. Xu noted. Depression and diseases like Parkinson's and Alzheimer's are associated with changes deep inside the brain, and finding the cures could be helped by subcortical neural imaging—below the gray matter, into the white matter and beyond, if the brain is visualized as stacked layers. If 3-photon microscopy can be used to map the entire brain, it could pave the way to new breakthroughs in neuroscience as well as other clinically relevant areas.

Related Links:

Cornell University

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.